Full text is available at the source.
Abstract
Metabolic syndrome (MetS) is closely linked with type 2 diabetes mellitus (T2DM), increasing cardiovascular and metabolic disease risk.
- MetS includes features such as central obesity, high triglyceride levels, low HDL cholesterol, high blood pressure, and impaired fasting glucose.
- The relationship between MetS and T2DM is bidirectional, meaning each condition can influence the other.
- Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists may help manage issues associated with MetS.
- These medications could improve blood sugar control and offer potential benefits for heart and kidney health in individuals with T2DM.
Simplified